- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic lymphocytic leukaemia or small lymphocytic lymphoma.
- Meeting Date: March 2023
- Public Summary Document (PSD) March 2023 PBAC Meeting - (PDF 520KB)
- Public Summary Document (PSD) March 2023 PBAC Meeting - (Word 192KB)
Acalabrutinib – March 2023
Acalabrutinib: Capsule 100 mg; Calquence®
Last updated
14 July 2023